UNITED STATES ANTIMONY CORP
UAMYDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
UAMY Earnings Report
EPS Est: $-0.02 | FQ end 2026-06
How UAMY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UB-421 | Phase 2 | HIV-1 Infection | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in UNITED STATES ANTIMONY CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in UNITED STATES ANTIMONY CORP's (UAMY) pipeline across Phase 2. Its lead program is UB-421 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UNITED STATES ANTIMONY CORP's next FDA catalyst?→
UNITED STATES ANTIMONY CORP's (UAMY) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track UAMY biotech catalysts?→
Add UAMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UNITED STATES ANTIMONY CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.